Nonalcoholic Fatty Liver Disease Severity Is Related to Plasma Pro-Oxidative Biomarkers Rather Than Liver Tissue-Measured Nitrogen Metabolism Biomarkers in Population with Obesity and Metabolic Syndrome

Suárez‐Cuenca, Juan Antonio; Domínguez-Pérez, Gabriela Alexandra; Hernández‐Muñoz, Rolando; Hernández-Patricio, Alejandro; Vera-Gómez, Eduardo; Gutiérrez-Buendía, Juan Ariel; Salamanca-García, Moisés; Montoya-Ramírez, Jesús; Gaytán-Fuentes, Omar Felipe; Aranda-Rodríguez, Carolina; Rojas-Noverón, Amy R.; García, Silvia; Mondragón-Terán, Paul

doi:10.1089/met.2022.0007

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The accumulation of nitrite (an indicator of nitric oxide production) in the plasma was determined by a colorimetric assay 12 . Gris's reagent (0.1% N-(1-naphthyl) ethylene diamine dihydrochloride, 1% sulfanilamide, and 2.5% phosphoric acid) was used.…”

Section: Estimation Of Nitritementioning

confidence: 99%

Untitled

2024

IJPSR

View full text Add to dashboard Cite

Background: Sinigrin (allyl-glucosinolate or 2-propenylglucosinolate), an aliphatic glucosinolate, is naturally present in Brassicaceae plants, while carvacrol (2-methyl-5-isopropylphenol) is a monoterpene phenolic component of the essential oil generated by many aromatic plants. This study is aimed to determine the hepatoprotective potential of these phytoconstituents on Paracetamol-induced liver damage in Wistar rats. Methods: Seven groups of six Wistar rats, each weighing between 180 and 230 g, were selected. The animals' weight range was evenly divided throughout the groups. The control group, group I, got normal saline; the PCM group, group II, received paracetamol (3 g/kg, p.o.); groups III and IV, carvacrol (25, 50 mg/kg/p.o.); and the groups V and VI, sinigrin (25, 50 mg/kg/p.o.) once daily for 14 days. Silymarin was given daily to group VII-Standard at a dose of 25 mg/kg p.o. Result: Serum samples were used to determine levels of marker enzymes such as aspartate transaminases (AST), alanine transaminases, lactate dehydrogenase (LDH), alkaline phosphatase (ALP), and glutamyl transpeptidase (GGT). The proinflammatory cytokines interleukin-1beta (IL-1b) and interleukin-6 (IL-6) as well as nitrite levels and catalase activity all decreased in carvacrol and sinigrin-treated rats in a dosedependent manner. Conclusion: The present study will provide scientific data and justify their traditional uses to treat various liver problems. This study confirmed that carvacrol and sinigrin have hepatoprotective potential against Drug Induced Liver Injury (DLI).

show abstract

Section: Estimation Of Nitritementioning

confidence: 99%

Untitled

2024

IJPSR

View full text Add to dashboard Cite

show abstract

“…In addition, they also suggested that quantification of 4-HNE by immunohistochemistry is assessable of hepatic lipid peroxidation. A recent study demonstrated that plasma pro-oxidative biomarkers are more related to the severity of NAFLD than nitrogen metabolism biomarkers measured in the liver tissue [ 35 ]. However, oxidative stress and nitrogen metabolism biomarkers are yet incomprehensively evaluated in terms of NAFLD-related atherosclerosis and cardiovascular disease.…”

Section: Oxidative Stress In Nafldmentioning

confidence: 99%

Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia

Lim¹,

Jeong²,

Hong³

et al. 2023

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to increase to over half of the adult population by 2040 globally. Since the final diagnosis of NAFLD is made by a liver biopsy, several non-invasive approaches have been developed and validated to define NAFLD and evaluate NAFLD-associated diseases. Presently, NAFLD has been identified as an important and independent risk factor for developing several extrahepatic diseases, including atherosclerosis, cardiovascular disease (CVD), diabetes, and dementia. This review discusses current findings of up-to-date literature regarding the effects of NAFLD on the risk of atherosclerosis and CVD in Asia along with potential underlying biological mechanisms and therapeutic approaches to lower the NAFLD-related CVD risk. We further focus on the difference between NAFLD and metabolic dysfunction-associated fatty liver disease (MAFLD) on the risk of CVD and its implication by comparing the risk of NAFLD and MAFLD.

show abstract